We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Genenta Science SPA | NASDAQ:GNTA | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.017 | -0.55% | 3.083 | 1.24 | 4.83 | 3.12 | 3.06 | 3.10 | 4,641 | 21:23:53 |
From Jul 2019 to Jul 2024
DOW JONES NEWSWIRES
Genta Inc. (GNTA) said the Food and Drug Administration has recommended a clinical trial for its cancer drug Genasense.
The FDA's Center for Drug Evaluation and Research ruled that available data are not adequate to support approval of the treatment for patients with chronic lymphocytic leukemia.
The biopharmaceutical company's chief medical officer, Dr. Loretta M. Itri, said the company would discuss the matter with clinical and regulatory authorities before deciding its next steps.
-By Kathy Shwiff, Dow Jones Newswires; 201-938-5975; Kathy.Shwiff@dowjones.com
1 Year Genenta Science Chart |
1 Month Genenta Science Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
